Loading...

NAOV NANOVIBRONIX INC Delisting Actions 8-K Filing

NNVB

NV

NANOVIBRONIX INC

(NAOV)

2025 8-K

Name Change Announcement

Board Changes Announced

Shareholder Letter Issued

Securities Offering

Management Changes

Equity Offerings

Reverse Stock Split

Changes in Rights of Securi...

Equity Offerings

Promissory Note Issued

Director Resignation

Health Study Announcement

Stockholder Meeting

Merger Completion

Equity Issuance

Nasdaq Compliance

Annual Meeting Results

Stockholder Meeting

Contract Renewal

Nasdaq Delisting Notice

Nasdaq Delisting Notice

Annual Meeting Notice

Management Changes

Financial Update

Financial Update

Agreement with Veranex, Inc.

Cancellation of Special Mee...

Dismissal of Independent Re...

Departure of Directors or C...

Agreement Announcement

Nasdaq Compliance

Regulation FD Disclosure

Approval Announcement

Private Placement

Distribution Agreement Amen...

Delisting due to Non-Compli...

Distribution Agreement

Regulation FD Disclosure

Annual Meeting Announcement

Announcement of PainShield ...

Product Trial Results Annou...

Compliance Announcement

Reverse Stock Split

Regulation FD Disclosure

External Links:

NanoVibronix Inc announced the completion of the first phase of a randomized control trial for its UroShield device and received a limited extension from Nasdaq to comply with listing requirements, including a reverse stock split by February 27, 2025.

AI Assistant

NANOVIBRONIX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.